Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight

Norihiro Sato, Shiro Kohi, Keiji Hirata, Michael Goggins

Research output: Contribution to journalReview articlepeer-review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains the most deadly disease worldwide, with the lowest survival rate among all cancer types. Recent evidence suggests that hyaluronan (HA), a major component of ECM, provides a favorable microenvironment for cancer progression. Pancreatic ductal adenocarcinoma is typically characterized by a dense desmoplastic stroma containing a large amount of HA. Accumulation of HA promotes tumor growth in mice and correlates with poor prognosis in patients with PDAC. Because HA is involved in various malignant behaviors of cancer (such as increased cell proliferation, migration, invasion, angiogenesis, and chemoresistance), inhibiting HA synthesis/signaling or depleting HA in tumor stroma could represent a promising therapeutic strategy against PDAC. In this review article, we summarize our current understanding of the role of HA in the progression of PDAC and discuss possible therapeutic approaches targeting HA. We summarize our current understanding of the role of hyaluronan in the progression of pancreatic ductal adenocarcinoma and discuss possible therapeutic approaches targeting HA.

Original languageEnglish (US)
Pages (from-to)569-575
Number of pages7
JournalCancer Science
Volume107
Issue number5
DOIs
StatePublished - May 1 2016

Keywords

  • Desmoplasia
  • Hyaluronan
  • Pancreatic ductal adenocarcinoma
  • Tumor stroma
  • Tumor-stroma interaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight'. Together they form a unique fingerprint.

Cite this